FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

П										
1	OMB Number:	3235-0287								
1	1									
н	Estimated average hurden									

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Snow David P.						2. Issuer Name and Ticker or Trading Symbol Eloxx Pharmaceuticals, Inc. [ELOX]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Volter (specify						
(Last) (First) (Middle) C/O ELOXX PHARMACEUTICALS, INC. 950 WINTER STREET					01	3. Date of Earliest Transaction (Month/Day/Year) 01/30/2020								FORMER CHIEF BUSINESS OFFICER						
(Street) WALTHAM MA 02451						4. If Amendment, Date of Original Filed (Month/Day/Year) 01/31/2020									6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)																	
		Tak	ole I - Nor	n-Deriv	vativ	e Se	curi	ties Ac	quired,	Dis	posed o	f, or Be	enefic	ially	Owned					
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)						Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)				4 and Securitie Benefici		s ally ollowing	Form (D) o	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount	(A) (D)	or Pr	ice	Transacti (Instr. 3 a	tion(s)			(111311.4)	
Common Stock 01/30/					0/202	/2020		M		6,250) A		\$0 ⁽¹⁾	6,2	,250		D			
Common Stock 01/30/				0/202	1/2020		F		2,045	D	\$	3.91	4,2	205		D				
			Table II -								osed of, onvertil				Owned		,			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Date,	Code (Instr.				6. Date Exercisable Expiration Date (Month/Day/Year)		Amount of			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership tt (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amo or Nun of Sha	ber		(Instr. 4)				
Restricted Stock	(1)(2)	01/30/2020			М			6,250 ⁽³⁾	(1)		(1)	Common	6,2	:50	\$0 ⁽⁴⁾	18,750	(5)	D		

Explanation of Responses:

- 1. Reflects the restricted stock units issued to the reporting person on January 30, 2019 which have partially vested and settled for shares of the issuer's common stock. The original Form 4 filed on January 31, 2020 is amended in its entirety by this Form 4 Amendment to provide the: (a) correct date the restricted stock units were first issued to the reporting person; and (b) correct disposition of the derivative securities.
- 2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- 3. The original Form 4 filed on January 31, 2020 is amended by this Form 4 Amendment to correctly identify the nature of the transaction of the reporting person
- ${\it 4. The restricted stock units were issued pursuant to the Issuer's 2018 \ Equity \ Incentive \ Plan.}$
- 5. The remaining restricted stock units will vest ratably each quarter through January 30, 2023, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain

/s/ Neil S. Belloff, Attorney-in-03/04/2020 **Fact**

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.